Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Severe placental lesions due to maternal SARS-CoV-2 infection associated to intrauterine fetal death

Charlotte Dubucs MDa,b,i,*, Marion Groussolles MDC,j, Jessie Ousselin Medical residenta, Agnès Sartor MDC,d, Nathalie Van Acker MSc,PhDa,e, Christophe Vayssière MDPd,e,f, Christophe Pasquier MDPd,f, Joëlle Reyre MDg, Laïa Batlle MDh, Stéphanie Favarel clinical research associate c, Delphine Duchanois midwife c, Valérie Jauffret clinical research associate c, Monique Courtaud-Saïdi MDPa, Jacqueline Aziza MDA,i

a Département d’anatomie et Cytologie Pathologiques, IUCT-Oncopole, 31059 Cedex, France 
b Service de Génétique Médicale, CHU Toulouse, 31059, France 
c UROG (Unité de Recherche en Obstétrique et Gynécologie), Maternité Paule de Viguier, 31059 Cedex, Toulouse, France 
d Service de Gynécologie Obstétrique, Maternité Paule de Viguier, CHU Toulouse, 31059, France 
e Département d’anatomie et Cytologie Pathologiques, CHU, Imag’IN Platform, IUCT-Oncopole, Toulouse 31059, France 
f Service de Virologie, CHU Toulouse, 31059, France 
g MEDIPATH-Laboratoire des Feuillants, Toulouse, 31100, France 
h Service de Gynécologie-Obstétrique, Hôpital Joseph Ducuing, Toulouse, 31300, France 
i Member of the SOFFOET (Société Française de Fœtopathologie), 2 avenue du Professeur Léon Bernard, Faculté de Médecine, CS 34317, 35043 Rennes, France 
j SPHERE - Equipe Constitutive du CERPOP, UMR 1295, Unité Mixte de Recherche Inserm — Université Toulouse III Paul Sabatier, 31000, France

Received 22 November 2021; revised 23 December 2021; accepted 30 December 2021

Available online 5 January 2022

Keywords: Intrauterine fetal death; SARS-CoV-2 infection; Pregnancy;

Summary Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can cause severe placental lesions leading rapidly to intrauterine fetal death (IUFD). From August 2020 to September 2021, in the pathology department of Toulouse Oncopole, we analyzed 50 placentas from COVID-19—positive unvaccinated mothers.
The purpose of our study is to describe the clinicopathological characteristics of these placental damages and to understand the pathophysiology.

Ten of them (20%) showed placental lesions with positive immunohistochemistry for SARS-CoV-2 in villous trophoblasts. In five cases (10%), we observed massive placental damage associating trophoblastic necrosis, fibrinous deposits, intervillositis, as well as extensive hemorrhagic changes due to SARS-CoV-2 infection probably responsible of IUFD by functional placental insufficiency. In five other cases, we found similar placental lesions but with a focal distribution that did not lead to IUFD but live birth.

These lesions are independent of maternal clinical severity of COVID-19 infection because they occur despite mild maternal symptoms and are therefore difficult to predict. In our cases, they occurred 1–3 weeks after positive SARS-CoV-2 maternal real-time polymerase chain reaction testing and were observed in the 2nd and 3rd trimesters of pregnancies. When these lesions are focal, they do not lead to IUFD and can be involved in intrauterine growth restriction.

Our findings, together with recent observations, suggest that future pregnancy guidance should include stricter pandemic precautions such as screening for a wider array of COVID-19 symptoms, enhanced ultrasound monitoring, as well as newborn medical surveillance.

© 2022 Elsevier Inc. All rights reserved.

1. Introduction

Vertical transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and pregnancy complications induction are serious concerns for pregnant individuals with COVID-19. Based on early RNA detection of SARS-CoV-2 after birth, vertical transmission’s incidence of SARS-CoV-2 has been estimated to occur in around 2–3% of neonates [1,2]. The short- and long-term consequences of this infection on the newborn are still poorly understood. However, even if a neonate tests negative for SARS-CoV-2, different abnormal placental findings have been reported in cases of COVID-19—positive mothers [3]. Since the beginning of the pandemic, many nonspecific placental lesions have been described, including fetal and maternal vascular malperfusion, or chorioamnionitis, all negative in immunohistochemistry with the anti—SARS-CoV-2 antibody [4]. On the other hand, lesions characterized by trophoblastic necrosis, fibrinous deposits, and intervillositis are more suggestive of viral involvement and can lead to IUFD [5].

The purpose of our study is to describe the clinicopathological characteristics of placental damages associated with SARS-CoV-2 maternal infection in 50 placentas from COVID-19—positive unvaccinated mothers and to understand the pathophysiology. Histopathological findings are heterogeneous. Among positive SARS-CoV-2 placentas, specific histological findings are extremely variable in intensity from diffuse placental hemorrhagic lesions to focal perivillous fibrin deposition lesions possibly sequel.

2. Materials and methods

From August 2020 to September 2021, in the pathology department of Toulouse Oncopole (attached to the biggest maternity unit in Occitania [south of France] with more than 5000 births a year), we analyzed fifty placentas from COVID-19—positive unvaccinated mothers. Forty of them were normal or nonspecific at histological examination, whereas 10 of them showed particular abnormal histological signs reported here.

2.1. Immunohistochemistry

Automated classical immunohistochemical (IHC) stains were performed using the Benchmark ULTRA (Roche, Ventana Medical Systems, Innovation Park Drive Tucson, Arizona 85755, USA) on formalin-fixed and paraffin-embedded (FFPE) tissue sections (3 μm). After dewaxing, tissue slides were heat pretreated using a CC1 (pH8) buffer (05424569001, Roche) for 64 min at 98 °C. The slides were blocked for endogenous peroxidase activity and incubated with primary anti—2019-nCOV Spike rabbit polyclonal (A20022, ABclonal, Diagomics, Blagnac, France) (1/100 in Envision FLEX antibody diluent, K800621-2, Agilent, Santa Clara, CA 95051, USA) and anti—SARS-CoV-2 nucleocapsid mouse monoclonal (Ready to Use, clone BSB-134, BioSB, Diagomics, Blagnac, France) antibodies for 64 and 92 min, respectively. After dewaxing, tissue slides were heat pretreated using a CC1 (pH8) buffer (05424569001, Roche) for 64 min at 98 °C. The slides were blocked for endogenous peroxidase activity and incubated with primary anti—2019-nCOV Spike rabbit polyclonal (A20022, ABclonal, Diagomics, Blagnac, France) (1/100 in Envision FLEX antibody diluent, K800621-2, Agilent, Santa Clara, CA 95051, USA) and anti—SARS-CoV-2 nucleocapsid mouse monoclonal (Ready to Use, clone BSB-134, BioSB, Diagomics, Blagnac, France) antibodies for 64 and 92 min, respectively. Targets were then visualized using the OptiView DAB detection kit (06396500001, Roche). The tissue slides were counterstained using hematoxylin (05277965001, Roche) for 8 min followed by postcoloration using Bluing...
Table 1  Pregnancy outcome and maternal and placental characteristics.

| Cases | Age of onset of maternal symptoms (WoG) | Term of delivery (WoG) | Time between maternal symptoms and delivery (days) | Pregnancy outcome | Maternal symptoms | Fetal weight (g) | Fetal weight (percentile) | Histological placental lesions |
|-------|----------------------------------------|------------------------|---------------------------------------------------|-------------------|-------------------|----------------|--------------------------|-------------------------------|
| 1     | 32                                     | 34 + 1                 | 15                                                | IUFD              | Influenza-like illness + hyperthermia | 1640           | 3-5th                    | Diffuse TN + intervillositis + PFD + IH |
| 2     | 21                                     | 23                     | 14                                                | IUFD              | Influenza-like illness               | 585            | <3rd                     | Diffuse TN + intervillositis + PFD + IH |
| 3     | 18 + 4                                 | 19 + 4                 | 7                                                 | IUFD              | Influenza-like illness               | 240            | <3rd                     | Diffuse TN + intervillositis + PFD + IH |
| 4     | 19 + 3                                 | 21                     | 11                                                | IUFD              | Hyperthermie                        | 380            | 10-25th                  | Diffuse TN + intervillositis + PFD + IH |
| 5     | 34                                     | 36 + 6                 | 20                                                | IUFD              | Influenza-like illness               | 2990           | 50th                     | Diffuse TN + intervillositis + PFD + IH |
| 6     | unknown                                | 38 + 5                 | unknown                                           | Cesarean section for bradycardia and preeclampsia live newborn | Hyperthermia          | 2440           | <5th                     | Focal TN + intervillositis + PFD   |
| 7     | 30                                     | 33                     | 21                                                | Cesarean section live newborn | Influenza-like illness               | 1940           | 20-50th                  | Focal TN + intervillositis + PFD   |
| 8     | 33                                     | 33                     | 0                                                 | Cesarean section live newborn | Influenza-like illness               | 1730           | 30th                     | Focal TN + intervillositis + PFD   |
| 9     | 35                                     | 37 + 3                 | 18                                                | Cesarean section live newborn | Asymptomatic            | 2465           | 10-25th                  | Focal TN + intervillositis + PFD   |
| 10    | 35 + 4                                 | 40 + 4                 | 35                                                | Vaginal delivery live newborn | Hyperthermia          | 2860           | 5-10th                   | Focal TN + intervillositis + PFD   |
| 11    | 32                                     | 39                     | 49                                                | Vaginal delivery live newborn | Influenza-like illness               | 2550           | 3-5th                    | Focal TN + intervillositis + PFD   |
| 12    | 25                                     | 36 + 5                 | 82                                                | Vaginal delivery live newborn | Hypoxemic pneumonia          | 4250           | 95th                     | Normal                           |
| 13    | 31                                     | 32                     | 7                                                 | Cesarean section live newborn | Hypoxemic pneumonia          | 1800           | 70th                     | Normal                           |
| 14    | 32                                     | 33                     | 7                                                 | Cesarean section live newborn | Influenza-like illness               | 1700           | 30th                     | Normal                           |
| 15    | 31 + 3                                 | 37                     | 45                                                | Cesarean section live newborn | Asymptomatic            | 3100           | >75th                    | Normal                           |
| 16    | 30                                     | 30 + 5                 | 5                                                 | Cesarean section live newborn | Hypoxemic pneumonia          | 1600           | >50th                    | MVM                              |
| 17    | 39                                     | 41                     | 14                                                | Vaginal delivery live newborn | Asymptomatic            | 4210           | >95th                    | MVM                              |
| 18    | 35                                     | 39 + 4                 | 32                                                | Vaginal delivery live newborn | Asymptomatic            | 3350           | >95th                    | Normal                           |
| 19    | 38 + 2                                 | 39 + 2                 | 7                                                 | Cesarean section live newborn | Unknown                | 2890           | 25th                     | Normal                           |
| 20    | 29 + 2                                 | 30                     | 5                                                 | Cesarean section live newborn | Hypoxemic pneumonia          | 1620           | >75th                    | Chorangiosis                      |
| 21    | 28                                     | 28 + 2                 | 2                                                 | Cesarean section live newborn | Hypoxemic pneumonia          | 1100           | >50th                    | Chorangiosis                      |
| No. | OGA | OGB | OGC | OGD | Delivery | Diagnosis | Week | Site |
|-----|-----|-----|-----|-----|----------|-----------|------|------|
| 22  | 37  | 39 + 1 | 15 |  | Vaginal delivery live newborn | Unknown | 2250 | <3rd | MVM |
| 23  | 35  | 38 + 1 | 22 |  | Vaginal delivery live newborn | Hypoxemic pneumonia | 3350 | >75th | Normal |
| 24  | 33 + 2 | 34 + 1 | 6  |  | Cesarean section live newborn | Hypoxemic pneumonia | 1935 | >25th | MVM |
| 25  | 13  | 40 + 6 | 195 |  | Vaginal delivery live newborn | Influenza-like illness | 2680 | <3rd | MVM |
| 26  | 34 + 2 | 41 + 5 | 46 |  | Vaginal delivery live newborn | Hypoxemic pneumonia | 3300 | 25th | Normal |
| 27  | 28  | 33 + 3 | 38 |  | Vaginal delivery live newborn | Unknown | 2130 | >75th | MVM |
| 28  | 25  | 40 + 4 | 109 |  | Vaginal delivery live newborn | Influenza-like illness | 3730 | 59th | Normal |
| 29  | 34 + 3 | 39 + 4 | 36 |  | Vaginal delivery live newborn | Unknown | 3120 | >25th | MVM |
| 30  | 26  | 38 + 2 | 86 |  | Vaginal delivery live newborn | Unknown | 2990 | 47th | Normal |
| 31  | 31 + 4 | 32 + 6 | 9 |  | Vaginal delivery live newborn | Hypoxemic pneumonia | 1505 | 25th | FVM |
| 32  | Unknown | 29 | Unknown |  | Vaginal delivery live newborn | Unknown | 1230 | >50th | Chorioamnionitis |
| 33  | 34 + 5 | 34 + 6 | 1 |  | Cesarean section live newborn | Asymptomatic | 2350 | >25th | MVM |
| 34  | 17  | 18 + 5 | 12 |  | Twins pregnancy: miscarriage | Unknown | 120 and 240 | 10th and | Chorioamnionitis |
| 35  | 36  | 39 | 21 |  | Vaginal delivery live newborn | Asymptomatic | 3840 | >95th | Normal |
| 36  | 21  | 38 | 119 |  | Vaginal delivery live newborn | Influenza-like illness | 3715 | >95th | MVM |
| 37  | 32  | 39 | 49 |  | Vaginal delivery live newborn | Influenza-like illness | 3440 | >50th | Normal |
| 38  | 33 + 1 | 41 | 55 |  | Vaginal delivery live newborn | Unknown | 4200 | 90th | MVM + chorioamnionitis |
| 39  | 31  | 37 | 42 |  | Vaginal delivery live newborn | Unknown | 3390 | >75th | Normal |
| 40  | 4   | 41 | 259 |  | Vaginal delivery live newborn | Influenza-like illness | Unknown | x | Normal |
| 41  | 10  | 39 + 6 | 209 |  | Vaginal delivery live newborn | Unknown | 3090 | 20th | Focal intervillositis |
| 42  | 28  | 39 | 77 |  | Vaginal delivery live newborn | Influenza-like illness | 3470 | 47th | Chorioamnionitis |
| 43  | 4   | 39 | 245 |  | Vaginal delivery live newborn | Unknown | 3600 | 75th | Normal |
| 44  | 34 + 3 | 39 + 4 | 36 |  | Vaginal delivery live newborn | Unknown | 3120 | 25th | MVM |
| 45  | 18 + 5 | 28 + 5 | 70 |  | Vaginal delivery live newborn | Unknown | 1030 and | 25th and | MVM |
|     |     |     |     |     |     |     |   1220 | 50th |         |
| 46  | 34  | 40 + 4 | 46 |  | Vaginal delivery live newborn | Unknown | 3470 | 60th | Chorioamnionitis |
| 47  | 32  | 40 + 2 | 58 |  | Vaginal delivery live newborn | Unknown | Unkwon | X | MVM + chorioamnionitis |
| 48  | 13  | 23 + 3 | 73 |  | Miscarriage | 430 | NA | X | MVM + chorioamnionitis |
| 49  | 20 + 3 | 40 + 3 | 143 |  | Vaginal delivery live newborn | Unknown | 3260 | 40th | MVM + chorioamnionitis |
| 50  | 24  | 39 + 5 | 110 |  | Vaginal delivery live newborn | Unknown | 3260 | 25th | MVM |

Abbreviations: IUFD, intrauterine fetal death; TN, trophoblastic necrosis; PFD, perivillous fibrin deposition; IH, intervillous hemorrhage; MVM, maternal vascular malperfusion; FVM, fetal vascular malperfusion.
reagent for 4 min at room temperature (05266769001, Roche). The slides were then dehydrated (ethanol and xylene) and mounted using xylene-based mounting (TissueTek Prisma®, Sakura Finetek Europe B.V., The Netherlands).

2.2. SARS-CoV-2 real-time polymerase chain reaction

SARS-CoV-2 genomic RNA was detected on the specimen taken by nasopharyngeal swabs by Hologic Aptima SARS-CoV-2 transcription-mediated amplification on the Panther instrument as recommended by the manufacturer. For SARS-CoV-2 genomic RNA detection on placenta, samples were crushed and nucleic acids extracted using MagNA Pure 96 small volume protocol (Roche Diagnostics). The targets were localized on the RNA-dependent polymerase gene (IP2 and IP4, Institut Pasteur, Paris, France). Amplification and real-time detection were performed using qScript XLT 1-step RT-qPCR ToughMix (Quantabio, VWR International SAS, France) on Light Cycler 480 (Roche Diagnostics).

3. Results

In our study, 40 of the 50 placentas analyzed showed histological findings either normal (n = 16/40, 40%) or with various nonspecific lesions as previously described in the literature [4,6,7] such as fetal vascular malperfusion (n = 1/40) and maternal vascular malperfusion (n = 17/40, 42.5%), chorioamnionitis (n = 8/40, 20%), or focal intervillitis (n = 1/40) (Table 1) according to the Amsterdam Placental Consensus classification [8]. All these cases were negative with anti–SARS-CoV-2 antibody and real-time polymerase chain reaction (RT-PCR) in the placenta. Thirty-eight of them were associated with live births; the two other cases were late miscarriages, one associated with a monochorionic diamniotic twin pregnancy with transfused transfusion syndrome and one in a context of septate uterus with a history of multiple miscarriages.

Among the 10 cases with significant placental lesions, five were associated with IUFD, whereas the other five were associated with live birth.

Five of the ten patients (Cases n°1–5) were hospitalized in our department for IUFD discovered between 19 weeks of gestation (WoG) and 36 + 6 WoG. None of them had a medical history. The pregnancy was marked by maternal COVID-19 infection between 18 + 4 WoG and 34 WoG, therefore between 1 and 3 weeks before IUFD occurred. Maternal symptoms were unspecific and mild, mainly hyperthermia (detailed in Table 1). Interestingly, three of them were tested for SARS-CoV-2 by nasopharyngeal swabs not because of symptoms suggestive of COVID but because they were considered contact cases. All five patients presented in our emergency unit for decreased fetal movements. Ultrasound examination discovered IUFD with a variable estimated fetal weight from <3rd percentile to 50th percentile. The standard IUFD examinations (CGH array, CMV, and Parvovirus B19 research in amniotic fluid, as well as maternal autoimmune tests excluding other causes of IUFD) were negative in the five cases. Placental bacteriology came back negative as well. All five placentas weighed within 10th-25th percentile for reference ranges. Cross-placental examination revealed unusual diffuse macroscopic lesions, characterized by several intraplacental and subchorial hematoma, dissociating the placenta tissue (Fig. 1, A3). These lesions involved at least 80% of the parenchyma.

Histologically, lesions were characterized by massive hemorrhagic inundation of intervillous space and extensive villous trophoblastic necrosis (Fig. 1, B1, D1-2, E). Surrounding the villi, chronic intervillitis and fibrin deposits were present (Fig. 1, B2, E2). Polymorphonuclears were observed, owing to hemorrhagic lesions. At high magnification, villous trophoblasts showed signs of cellular injury including karyorrhexis, fragmentation of trophoblast nuclei, and clearing of cytoplasm (Fig. 1, D3). Neither intravillous inflammation nor vascular thrombosis in villous capillaries was detected.

Viral immunostaining with SARS-CoV-2 antibodies (anti–SARS-CoV-2 nucleocapsid antibody and anti–SARS-CoV-2 spike antibody) was positive in syncytiotrophoblasts, cytotrophoblasts, but not endothelial cells (Fig. 1, C1-3, F). Intense positive cytoplasmic staining was

![Fig. 1](image-url)
observed in villous trophoblasts with anti–SARS-CoV-2 nucleocapsid (N) antibody (Fig. 1, C1, F). Immunostaining with anti–SARS-CoV-2-spike (S) antibody showed granular cytoplasmic staining (Fig. 1, C3). Detection of SARS-CoV-2 RNA in placenta confirmed these results with low cycle threshold (Ct < 20) in favor of high levels of genomic SARS-CoV-2 RNA.

Associated chronic intervillous inflammatory infiltrate was characterized by abundant presence of T lymphocytes (CD3+, with no predominance of neither CD4+ nor CD8+ T-cell subsets) and CD68+ monocytic cells. Few mononuclear cells circulating in maternal vascular space also showed strong positivity with anti–SARS-CoV-2 nucleocapsid (N) antibody.

Among these five cases, two fetuses were autopsied and none had visceral malformation, nor visceral (lung, kidney, heart) positive SARS-CoV-2 immunostaining.

The five other cases (cases n°6–10) showed similar lesions associating trophoblastic necrosis, fibrinoid deposits, and intervillitis but focally located with less than 30% of the parenchyma involved (Fig. 2, A1). Immunostaining with anti–SARS-CoV-2 nucleocapsid (N) antibody showed positive cytoplasmic staining only located in pathological villous trophoblasts (Fig. 2, A2, A3). Likewise, the lymphohistiocytic infiltrate demonstrated by anti-CD3 and CD68 antibodies was limited to the lesion areas.

One case (n°10) was particularly interesting because placental histological examination showed pathological foci characterized by perivillous fibrin deposition surrounding necrotic villi. These lesions were less inflammatory with more fibrin deposits, in the process of organization. Immunohistochemical anti–SARS-CoV-2 staining was not diffusely detected in trophoblasts as observed in other cases, but was only very focally present (Fig. 2, B1, B2, B3). Clinically, the time from maternal infection to childbirth was more than 2 months.

4. Discussion

4.1. Placenta’s pathological lesions

In cases of maternal SARS-CoV-2 infection, most of the placental histopathological lesions largely reported were nonspecific such as fetal vascular malperfusion, maternal vascular malperfusion, chorangiosis, chorioamnionitis, and villitis [4,6,7]. Indeed 40 of the 50 placentas analyzed in our study (80%) showed histological findings either normal
or with various nonspecific lesions as previously described in the literature, and all these cases were negative with anti–SARS-CoV-2 antibody and RT-PCR.

However, 10 of the 50 placentas analyzed showed specific placental lesions directly linked to SARS-CoV-2 infection because all were positive with anti–SARS-CoV-2 antibody and SARS-CoV-2 RT-PCR. Depending on their intensity, these lesions had variable consequences on pregnancy outcome ranging from intrauterine growth restriction (IUGR) to IUFD by functional placental insufficiency.

### 4.1.1. Placental damages linked to SARS-CoV-2 infection associated to IUFD

In five cases (cases n°1–5), placental damage was diffuse, involving at least 80% of parenchyma. Lesions were characterized by unusual massive hemorrhagic inundation of intervillous space and extensive villous trophoblastic necrosis associated with chronic inter villitisis and fibrin deposits. Placental lesions observed in our cases were in agreement with the few IUFD cases described in literature but were additionally characterized by multiple intra-placental hemorrhagic lesions associated with extensive trophoblastic necrosis and chronic inter villitisis [5,9,10]. The trophoblastic necrosis showed disappearance of trophoblastic cytoplasmic membranes, enlarged nuclei often vesicular with diffuse fine chromatin, or fragmentation of trophoblast nuclei possibly suggestive of viral toxicity of SARS-CoV-2 infection (Fig. 1, D3). This was supported by immunohistochemical studies showing positivity of villous trophoblast with SARS-CoV-2 antibodies. Otherwise, decidua arteriopathy was not seen but rather hemorrhagic changes dissociating the decidua, which is in agreement with literature [11]. Unlike other authors, we did not find fetal vascular thrombi [12].

The fact that these lesions were unusually intense and largely diffuse, both inflammatory and hemorrhagic, seems sufficient to explain functional placental insufficiency and its involvement in the fetal death due to placental destruction, especially because the IUFD assessment was negative.

On the clinical level, these lesions were observed between the 7th day and the 20th day after maternal infection occurred which is in agreement with the observation in the literature [11].

It is interesting to point out that hemorrhagic changes were especially marked in the diffuse placental damage associated to poor fetal outcome. These hematomas because of their intensity are unusual and cannot be explained by caesarian section.

Interestingly, Flores et al. analyzed the impact of COVID-19 infection on placental endothelium, by analyzing expression of von Willebrand factor (vWF), claudin-5, and vascular endothelial cadherin (VEC) in placentas of women with severe COVID-19 [13]. Their results showed an increase in the expression of vWF, suggesting the existence of a vascular thrombotic condition, and a decreased expression of both claudin-5 and VEC. Thus, enhanced vessel permeability is possibly responsible for a possible breach in the maternal–fetal interface leading to hemorrhages in the decidua and the intervillous space.

In the setting of adults SARS-CoV-2 infections, hemorrhagic lesions affecting other different organs have also been described such as hemorrhagic colitis [14], hemorrhagic pericardial effusion with tamponade [15], and hemorrhagic encephalopathy related to blood–brain barrier breakdown [16,17]. Some authors have suggested that these lesions are the result of a cytokine storm syndrome responsible for widespread microvascular injury [18].

### 4.1.2. Focal lesions linked to SARS-CoV-2 infection

In five other cases (cases n°6–10), lesions were focal or multifocal mainly associated with IUGR and involved less than 30% of the parenchyma. On microscopic examination, several focal lesions were observed, still characterized by trophoblastic necrosis, chronic histiocytic inter villitisis, and perivillous fibrin deposition, contrasting with non-segmental areas. Hemorrhagic changes were absent or rare.

Immunohistochemistry with anti–SARS-CoV-2 antibody was in agreement with the histological aspect and showed diffuse trophoblastic positivity in the lesion foci, whereas no positivity was noted elsewhere.

Interestingly, in case 10, the time from maternal infection to childbirth was more than 2 months, which is much longer than the 3 weeks observed in IUFD cases. This could suggest that lesions induced by SARS-CoV-2 infection evolve over time with only focal or even negative immunostaining for SARS-CoV-2, making the histological diagnosis of SARS-CoV-2 infection difficult.

### 4.2. SARS-CoV-2 vertical transmission

Among placentas and neonates tested for SARS-CoV-2 infection, a minority of neonates (2–3%) and placental samples (around 20%) tested positive for SARS-CoV-2 infection from the infected mother. This is what we have as well in our study because 10 of the 50 placentas tested positive for SARS-CoV-2 (20%) [19].

On reminder, SARS-CoV-2 infects tissues via its receptor angiotensin-converting enzyme 2 (ACE2), and its entry into cells requires spike protein cleavage by the serine protease TMPRSS2. ACE2 is highly expressed in maternal–fetal interface cells, such as syncytiotrophoblasts and cytotrophoblasts from 7 weeks onward and across gestation with similar intensity and distribution of ACE2 staining [20,21]. It is believed that high cellular coexpression of ACE2 (allowing virus attachment in cells) and TMPRSS2 (allowing virus penetration in cells) is required for viral transmission [22]. However, this rare coexpression in placenta could explain the high heterogeneity of placental lesions and thus variable and low occurrence of SARS-CoV-2 transplacental infection [13], as we expose it in case n°10 where lesions were highly heterogeneous (Fig. 1, D).
Schwartz et al. summarized the spectrum of pathology findings from pregnant women with COVID-19 based on the infection status of their infants. Authors concluded that co-occurrence of chronic histiocytic intervillitis and trophoblastic necrosis appears to be a risk factor for placental infection with SARS-CoV-2 as well as for maternal–fetal viral transmission and suggest a potential mechanism by which the coronavirus can breach the maternal–fetal interface [5]. However, the intensity and acute onset of the placental lesions could explain the rare positive fetal cases described to date because the death occurs rapidly by placental functional insufficiency before a possible fetal viral diffusion.

4.3. Correlation between severity of maternal signs and placental damage

In our study, placental lesions did not appear to be correlated with maternal infection severity. Indeed, third trimester’s pregnant women placentas received in our laboratory showed subnormal placental examination while they presented severe symptoms with respiratory distress requiring emergency fetal extraction. On the other hand, second trimester’s or third trimester’s maternal infections have been reported several times with IUFD despite mild maternal COVID-19 symptoms [12,23—26]. This makes clinical monitoring difficult and raises the question of ultrasound monitoring. Retrospectively, we did not find any ultrasound finding in the five cases with IUFD and suggest a possible rapid and fulminant onset of placental damage within a period of 1–3 weeks.

5. Conclusion

SARS-CoV-2 infection can cause severe placental lesions associated with chronic inflammation with trophoblastic necrosis and massive hemorrhage leading rapidly to placental destruction and IUFD as observed in our laboratory. These lesions are independent of maternal symptoms because they occur despite mild maternal symptoms and are therefore difficult to predict. In our cases, they occurred 1–3 weeks after positive SARS-CoV-2 maternal RT-PCR testing and were observed in the 2nd and 3rd trimesters of pregnancy. IUFD associated to SARS-CoV-2 placental lesions is not so rare because in our study they occurred in 5 of 50 cases (10%). These lesions can also appear focally in the placenta and lead to live birth with sometimes IUGR. The discovery of such lesions in the placenta should initiate a medical monitoring of the newborns for which the long-term effects are not known to date. Moreover, focal SARS-CoV-2 lesions seem to evolve over time with more fibrin deposits, becoming difficult to diagnose because SARS-CoV-2 immunostaining could become negative. This study highlights the need for systematic placental and fetal gross and microscopic evaluation, which can help elucidate the pathophysiology of COVID-19.

Acknowledgments

We thank the regional agency of Occitania for its financial support dedicated to the virological analyses in pregnant women. Contributions: C. D. wrote the manuscript with support from M. G., V. J. S., F. D., D. D., J. R., and O. J. M. C. S. and J. A. helped supervise the project. M. G., A. S., L. B., and C. V. followed the clinical cases. C. P. did the viral experiments. N. V. A. organized the figure and did the immunohistochemistry perfection.

References

[1] Kotlyar AM, Grechukhina O, Chen A, Popkhadze S, Grimshaw A, Tal O, et al. Vertical transmission of coronavirus disease 2019: a systematic review and meta-analysis. Am J Obstet Gynecol 2021; 224:35—53 e33.
[2] Lamouroux A, Attie-Bitach T, Martinovic J, Leruez-Ville M, Ville Y. Evidence for and against vertical transmission for severe acute respiratory syndrome coronavirus 2. Am J Obstet Gynecol 2020;223:91 e91—4.
[3] Wong YP, Khong TY, Tan GC. The effects of COVID-19 on placenta and pregnancy: what do we know so far? Diagnostics (Basel) 2021; 11.
[4] Hecht JL, Quade B, Deshpande V, Mino-Kenudson M, Ting DT, Desai N, et al. SARS-CoV-2 can infect the placenta and is not associated with specific placental histopathology: a series of 19 placentas from COVID-19-positive mothers. Mod Pathol 2020;33: 2092—103.
[5] Schwartz DA, Morotti D. Placental pathology of COVID-19 with and without fetal and neonatal infection: trophoblast necrosis and chronic histiocytic intervillitis as risk factors for transplacental transmission of SARS-CoV-2. Viruses 2020;12.
[6] Baergen RN, Heller DS. Placental pathology in covid-19 positive mothers: preliminary findings. Pediatr Dev Pathol 2020;23: 177—80.
[7] Shanes ED, Mithal LB, Otero S, Azad HA, Miller ES, Goldstein JA. Placental pathology in COVID-19. Am J Clin Pathol 2020;154: 23—32.
[8] Khong TY, Mooney EE, Ariel I, Balmus NC, Boyd TK, Brundler MA, et al. Sampling and definitions of placental lesions: Amsterdam placental workshop group Consensus statement. Arch Pathol Lab Med 2016;140:698—713.
[9] Bertero L, Borella F, Botta G, Carosso A, Cosma S, Bovetti M, et al. Placenta histopathology in SARS-CoV-2 infection: analysis of a consecutive series and comparison with control cohorts. Virchows Arch 2021;479:715—28.
[10] Hosier H, Farhadian SF, Morotti RA, Deshmukh U, Lu-Culligan A, Campbell KH, et al. SARS-CoV-2 infection of the placenta. J Clin Invest 2020;130:4947—53.
[11] Bouachra A, Allias F, Nadaud B, Massardier J, Mekki Y, Bouscambert Duchamp M, et al. Placental lesions and SARS-CoV-2 infection: diffuse placenta damage associated to poor fetal outcome. Placenta 2021;112:97—104.
[12] Gioia CD, Zullo F, Vecchio RCB, Pajno C, Perrone G, Galloppi P, et al. Stillbirth and fetal capillary infection by SARS-CoV-2. Am J Obstet Gynecol MFM 2021:100523.
[13] Flores-Piiego A, Miranda J, Vega-Torreblanca S, Valdespino-Vazquez Y, Helguera-Repetto C, Espejel-Nunez A, et al. Molecular insights into the thrombotic and microvascular injury in placental endothelium of women with mild or severe COVID-19. Cells 2021; 10:364. 10. Feb 10.
[14] Carvalho A, Alqasriri A, Adams A, Paul M, Kothari N, Peters S, et al. SARS-CoV-2 gastrointestinal infection causing hemorrhagic
colitis: implications for detection and transmission of COVID-19 disease. Am J Gastroenterol 2020;115:942–6.

[15] Foster B, Liaqat A, Chib A, Bolton SS, Kendig AC. An unusual presentation of COVID-19: hemorrhagic pericardial effusion with tamponade physiology. Cureus 2021;13:e13438.

[16] Krett JD, Jewett GAE, Elton-Lacasse C, Fonseca K, Hahn C, Au S, et al. Hemorrhagic encephalopathy associated with COVID-19. J Neuroimmunol 2020;346:577326.

[17] Chen Y, Xia F, Li Y, Li H, Ma L, Hu X, et al. Changes in characteristics, treatment and outcome in patients with hemorrhagic stroke during COVID-19. J Stroke Cerebrovasc Dis 2021;30:105536.

[18] Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. Hlh across Speciality Collaboration UK: COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:e1033–4.

[19] Sharps MC, Hayes DJL, Lee S, Zou Z, Brady CA, Almoghribi Y, et al. A structured review of placental morphology and histopathological lesions associated with SARS-CoV-2 infection. Placenta 2020;101:13–29.

[20] Cui D, Liu Y, Jiang X, Ding C, Poon LC, Wang H, et al. Single-cell RNA expression profiling of SARS-CoV-2-related ACE2 and TMPRSS2 in human trophoblast and placenta. Ultrasound Obstet Gynecol 2021;57:248–56.

[21] Gengler C, Dubuc E, Favre G, Greub G, de Leval L, Baud D. SARS-CoV-2 ACE-receptor detection in the placenta throughout pregnancy. Clin Microbiol Infect 2021;27:489–90.

[22] Pique-Regi R, Romero R, Tarca AL, Luca F, Xu Y, Alazizi A, et al. Does the human placenta express the canonical cell entry mediators for SARS-CoV-2? Elife 2020;9.

[23] Marinho PS, da Cunha A, Chimelli L, Avvad-Portari E, Andréuolo FDM, de Oliveira-Szejnfeld PS, et al. Case report: SARS-CoV-2 mother-to-child transmission and fetal death associated with severe placental thromboembolism. Front Med (Lausanne) 2021;8:677001.

[24] Poisson TM, Pierone Jr G. Placental pathology and fetal demise at 35 weeks of gestation in a woman with SARS-CoV-2 infection: a case report. Case Rep Womens Health 2021;30:e00289.

[25] Popescu DE, Cioca A, Muresan C, Navolan D, Gui A, Pop O, et al. A case of COVID-19 pregnancy complicated with hydrops fetalis and intrauterine death. Medicina (Kaunas) 2021;57:667.

[26] Richtmann R, Törloni MR, Oyamada Otani AR, Levi JE, Crema Tobara M, de Almeida Silva C, et al. Fetal deaths in pregnancies with SARS-CoV-2 infection in Brazil: a case series. Case Rep Womens Health 2020;27:e00243.